News

Filter

Current filters:

PharmaceuticalEylea

1 to 9 of 55 results

UPDATE: New study shows Regeneron’s Eylea is superior to rivals in DME

UPDATE: New study shows Regeneron’s Eylea is superior to rivals in DME

19-02-2015

US biotech Regeneron Pharmaceuticals today announced results from a study which show Eylea (aflibercept)…

AvastinEyleaLucentisOphthalmicsPharmaceuticalRegeneron PharmaceuticalsResearchUSA

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

16-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has compared trial data on German…

BayerEyleaGermanyLucentisNovartisOphthalmicsPharmaceuticalPricingRegulationRoche

Age-related macular degeneration treatment market to reach $10 billion by 2023

Age-related macular degeneration treatment market to reach $10 billion by 2023

04-12-2014

The market for treatments of age-related macular degeneration across seven major countries will almost…

AvastinEuropeEyleaFovistaLucentisMarkets & MarketingOphthalmicsPharmaceuticalUSA

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

Bayer’s Eylea approved in Japan for myopic CNV

Bayer’s Eylea approved in Japan for myopic CNV

22-09-2014

Bayer Yakuhin, the Japanese health care subsidiary if Germany’s Bayer has received approval from Japan’s…

BayerEyleaJapanOphthalmicsPharmaceuticalRegeneron PharmaceuticalsRegulation

Report shows Eylea and Lucentis are equally likely to be covered by payers

Report shows Eylea and Lucentis are equally likely to be covered by payers

19-09-2014

Recently launched anti-vascular endothelial growth factor (VEGF) agent Eylea (aflibercept), from USA-based…

EyleaFinancialGenentechLucentisOphthalmicsPharmaceuticalRegeneron PharmaceuticalsUSA

Eylea approved for diabetic macular edema in Europe

Eylea approved for diabetic macular edema in Europe

11-08-2014

The European Commission has approved German pharma major Bayer’s Eylea (aflibercept) injection for…

BayerEuropeEyleaOphthalmicsOphthalmologyPharmaceuticalRegeneronRegulation

1 to 9 of 55 results

Back to top